Zura Bio (NASDAQ:ZURA) Shares Up 5.6% – Still a Buy?

Zura Bio Limited (NASDAQ:ZURA)’s stock price was up 5.6% during trading on Wednesday . The stock traded as high as $5.46 and last traded at $5.3640. Approximately 121,596 shares changed hands during mid-day trading, a decline of 86% from the average daily volume of 843,188 shares. The stock had previously closed at $5.08.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the company. Oppenheimer cut their target price on Zura Bio from $16.00 to $15.00 and set an “outperform” rating on the stock in a research note on Friday, March 20th. Chardan Capital lifted their price target on Zura Bio from $10.00 to $11.00 and gave the stock a “buy” rating in a report on Monday, March 23rd. William Blair started coverage on Zura Bio in a research note on Wednesday. They issued an “outperform” rating for the company. Wedbush reaffirmed an “outperform” rating and set a $15.00 target price on shares of Zura Bio in a research report on Wednesday, July 1st. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Zura Bio in a research report on Monday. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Zura Bio currently has a consensus rating of “Moderate Buy” and a consensus price target of $10.75.

Zura Bio Stock Performance

The company has a market cap of $522.79 million, a PE ratio of -5.05 and a beta of -0.03. The company’s 50 day moving average price is $4.45 and its 200-day moving average price is $5.34.

Zura Bio (NASDAQ:ZURA) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.05). Equities research analysts expect that Zura Bio Limited will post -0.76 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Bank of America Corp DE raised its stake in Zura Bio by 31.9% in the 4th quarter. Bank of America Corp DE now owns 41,222 shares of the company’s stock valued at $103,000 after acquiring an additional 9,966 shares during the period. AQR Capital Management LLC bought a new position in Zura Bio during the first quarter worth about $72,000. JPMorgan Chase & Co. increased its stake in shares of Zura Bio by 78.7% in the second quarter. JPMorgan Chase & Co. now owns 4,659,951 shares of the company’s stock worth $4,893,000 after purchasing an additional 2,052,732 shares in the last quarter. Jane Street Group LLC purchased a new position in shares of Zura Bio in the second quarter worth about $113,000. Finally, Atika Capital Management LLC bought a new stake in shares of Zura Bio in the third quarter valued at approximately $1,195,000. Institutional investors own 61.14% of the company’s stock.

About Zura Bio

Zura Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation protein bioconjugates for therapeutic and diagnostic applications. Leveraging a proprietary platform for site-specific incorporation of non-canonical amino acids, the company aims to create highly targeted conjugates that improve drug delivery, enhance imaging contrast, and reduce off-target toxicity. Zura Bio’s technology is designed to streamline the manufacturing process by enabling precise attachment of payloads—such as cytotoxic drugs or imaging agents—to protein scaffolds without affecting their native structure or function.

The company’s research and development activities center on expanding its platform across multiple therapeutic areas, including oncology, immunology and rare diseases.